Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast
Authors:
- Yurdanur SulluYSYurdanur Sullu
- Guzin G. DemiragGDGuzin G. Demirag
- Arzu YildirimAYArzu Yildirim
- Filiz KaragozFKFiliz Karagoz
- Bedri KandemirBKBedri Kandemir
- 1 December 2011
- journal article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 207 (12) , 747-753
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Female Breast Cancer Status According to ER, PR and HER2 Expression: A Population Based AnalysisPathology and Oncology Research, 2011
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007
- Plasma Gelatinase Levels in Patients with Primary Breast Cancer in Relation to Axillary Lymph Node Status, Her2/neu Expression and other Clinicopathological VariablesClinical & Experimental Metastasis, 2005
- Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectivesClinical Chemistry and Laboratory Medicine (CCLM), 2004
- New functions for the matrix metalloproteinases in cancer progressionNature Reviews Cancer, 2002
- Metalloproteinases: role in breast carcinogenesis, invasion and metastasisBreast Cancer Research, 2000
- c-erbB-2 Is of Independent Prognostic Relevance in Gastric Cancer and Is Associated With the Expression of Tumor-Associated Protease SystemsJournal of Clinical Oncology, 2000
- Matrix metalloproteinases in tumour invasion and metastasisThe Journal of Pathology, 1999
- Transcription factors and breast cancerEndocrine-Related Cancer, 1998
- Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cellsClinical & Experimental Metastasis, 1997